EyeGene Inc. (KOSDAQ:A185490) announce a private placement of 1st tranche registered unsecured private convertible bonds for gross proceeds of KRW 5,400,000,000 on December 12, 2017. The transaction involves the participation of Korea Investment Global Pharmaceutical Industry Promotion PEF, G.N.TECH Venture Investment Fund 3, DSC Follow-on Growth Ladder Fund, DSC Promising Service Sector Fund. The bonds will now mature on December 14, 2021, and the conversion period will start from December 14, 2018 to December 07, 2021 The bonds carry a fixed coupon rate of 0.5% and yield to maturity of 3.75%.

The company will now issue 310,344 shares at a price of KRW 17,400 upon conversion. The expected payment date and subscription date is December 13, 2017 and December 14, 2017.